Erytech Pharma SA (ERYP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Erytech Pharma SA (ERYP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH132699D
  • |
  • Pages: 47
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Erytech Pharma SA (Erytech) is a clinical-stage biopharmaceutical company that offers development of therapies for rare forms of cancer and orphan diseases. The company develops pipeline of product candidates through its proprietary ERYCAPS platform. Its product candidates are intended for the treatment of acute myeloid leukemia, acute lymphoblastic leukemia, pancreatic cancer, non hodgkin lymphoma, and others. Erytech's pipeline products comprise eryasp, erymet, erymmune, and others. The company also develops other product candidates which uses encapsulated enzymes to induce tumor starvation. Erytech is headquartered in Lyon, France.

Erytech Pharma SA (ERYP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Erytech Pharma SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Erytech Pharma SA, Medical Devices Deals, 2011 to YTD 2017 10

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Erytech Pharma Raises USD3.95 Million in Venture Financing 12

Erytech Pharma Secures USD19.24 Million in Venture Funding 13

Partnerships 14

Erytech Pharma Enters into Research Agreement with Queen's University 14

Erytech Pharma Enters into Research Agreement with Fox Chase Cancer Center 15

Invetech Enters into Agreement with Erytech Pharma 16

ERYtech Pharma Enters Into Distribution Agreement With Teva For Graspa 17

Licensing Agreements 18

Erytech Pharma Enters Into Licensing Agreement With Orphan Europe For Graspa 18

Equity Offering 19

Erytech Pharma Raises USD74.7 Million in Private Placement of Shares 19

Erytech Pharma Raises USD11 Million in Private Placement of Shares 21

Erytech Pharma Raises USD27 Million in Private Placement of Shares 22

Erytech Pharma Plans to Raise Funds through Public Offering of Shares 24

Erytech Pharma Raises USD38 Million in Private Placement of Shares 25

Erytech Pharma Completes IPO For USD21 Million 26

Erytech Pharma SA-Key Competitors 28

Erytech Pharma SA-Key Employees 29

Erytech Pharma SA-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

May 18, 2017: ERYTECH Provides Business Update and Financial Highlights For Q1 2017 31

Nov 03, 2016: ERYTECH Provides Business Update and Reports Financial Highlights for Third Quarter 2016 33

Sep 06, 2016: ERYTECH Reports Business and Financial Update for the First Half of 2016 34

May 10, 2016: ERYTECH Provides Business and Financial Highlights for First Quarter 2016 35

Feb 23, 2016: ERYTECH Provides Business Update and Reports Financial Results for Full Year 2015 36

Jan 11, 2016: ERYTECH Reports Financial Highlights for Q4 2015 39

Corporate Communications 40

Oct 27, 2016: Erytech Strengthens Executive Leadership Team with Appointments of Chief Scientific Officer and Chief Business Officer 40

Sep 05, 2016: Erytech Appoints Allene M. Diaz To Its Board Of Directors 41

Clinical Trials 42

Mar 20, 2017: ERYTECH Presents New Preclinical Anti-Tumor Data on Erymethionase at AACR 2017 42

Jan 17, 2017: ERYTECH Presents New Preclinical Data on ERY-MET at the 2017 ASCO GI Symposium 44

Aug 29, 2016: ERYTECH Completes Patient Enrollment in Phase 2b Trial for eryaspase (GRASPA) in Acute Myeloid Leukemia 45

Jan 06, 2016: ERYTECH Announces Third DSMB Safety Review and Continuation of Its Phase 2b Study in Acute Myeloid Leukemia 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47

List of Figures

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Erytech Pharma SA, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Erytech Pharma SA, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Erytech Pharma SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Erytech Pharma SA, Deals By Therapy Area, 2011 to YTD 2017 9

Erytech Pharma SA, Medical Devices Deals, 2011 to YTD 2017 10

Erytech Pharma SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Erytech Pharma Raises USD3.95 Million in Venture Financing 12

Erytech Pharma Secures USD19.24 Million in Venture Funding 13

Erytech Pharma Enters into Research Agreement with Queen's University 14

Erytech Pharma Enters into Research Agreement with Fox Chase Cancer Center 15

Invetech Enters into Agreement with Erytech Pharma 16

ERYtech Pharma Enters Into Distribution Agreement With Teva For Graspa 17

Erytech Pharma Enters Into Licensing Agreement With Orphan Europe For Graspa 18

Erytech Pharma Raises USD74.7 Million in Private Placement of Shares 19

Erytech Pharma Raises USD11 Million in Private Placement of Shares 21

Erytech Pharma Raises USD27 Million in Private Placement of Shares 22

Erytech Pharma Plans to Raise Funds through Public Offering of Shares 24

Erytech Pharma Raises USD38 Million in Private Placement of Shares 25

Erytech Pharma Completes IPO For USD21 Million 26

Erytech Pharma SA, Key Competitors 28

Erytech Pharma SA, Key Employees 29

Erytech Pharma SA, Subsidiaries 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Erytech Pharma SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16140
Site License
USD 500 INR 32280
Corporate User License
USD 750 INR 48420

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com